baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 12/25 QIA/ DE000HD6NL73 /

07/11/2024 13:42:00	Chg.+0.0300	Bid07/11/2024	Ask07/11/2024	Underlying	Strike price	Expiration date	Option type
0.1600EUR	+23.08%	0.1500 Bid Size: 125,000	0.1600 Ask Size: 125,000	QIAGEN NV	55.00 -	17/12/2025	Call

GlobeNewswire 28/08 QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in c...

TeleTrader 26/08 Europe closes mixed amid Middle East crisis

GlobeNewswire 31/07 QIAGEN delivers solid performance and exceeds outlook for Q2 2024

GlobeNewswire 31/07 Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

GlobeNewswire 08/07 QIAGEN to enhance the identification of human remains of Indigenous people and African Americans

GlobeNewswire 02/07 QIAGEN N.V. to release results for Q2 2024 and hold webcast

GlobeNewswire 27/06 QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis in...

GlobeNewswire 17/06 QIAGEN announces 2028 strategy for solid profitable growth

GlobeNewswire 13/06 QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput N...

GlobeNewswire 12/06 QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to su...

GlobeNewswire 11/06 QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious dis...

GlobeNewswire 06/06 QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition per...

GlobeNewswire 05/06 QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of it...

GlobeNewswire 03/06 QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improv...

GlobeNewswire 30/05 QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global...

GlobeNewswire 29/05 QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision ...

GlobeNewswire 22/05 deepull appoints Didier Deltort to its Board of Directors

GlobeNewswire 14/05 QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical devic...

GlobeNewswire 13/05 QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accura...

GlobeNewswire 07/05 QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics

GlobeNewswire 07/05 Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq

GlobeNewswire 02/05 QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inher...

GlobeNewswire 29/04 QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance

UC WAR. CALL 12/25 QIA/ DE000HD6NL73 /

If you wish to receive reply to your feedback, please provide your email address.